Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2026 Mar 5;5(4):102640.
doi: 10.1016/j.jacadv.2026.102640. Online ahead of print.

Clinical Characteristics and Cardiac Magnetic Resonance Profile of PKP2 Variant-Positive Patients With a Hypertrophic Cardiomyopathy Phenotype

Matteo Castrichini  1 , Ramin Garmany  2 , Konstantinos C Siontis  1 , Darrell B Newman  1 , Jeffrey B Geske  1 , Steve R Ommen  1 , Jay Schneider  3 , Leslie T Cooper  3 , Michael J Ackerman  4 , John R Giudicessi  5
Affiliations

Clinical Characteristics and Cardiac Magnetic Resonance Profile of PKP2 Variant-Positive Patients With a Hypertrophic Cardiomyopathy Phenotype

Matteo Castrichini et al. JACC Adv. .
No abstract available

Keywords: PKP2; arrhythmogenic cardiomyopathy; genetics; hypertrophic cardiomyopathy.

PubMed Disclaimer

Conflict of interest statement

Funding support and author disclosures This work was supported by the Mayo Clinic Windland Smith Rice Comprehensive Sudden Cardiac Death Program (Dr Ackerman) and the Paul and Ruby Tsai and Family Fund for Hypertrophic Cardiomyopathy Research (Drs Ackerman and Giudicessi). Dr Ackerman is a consultant for Abbott, ARMGO Pharma, Boston Scientific, Bristol Myers Squibb, Illumina, Invitae, Medtronic, Tenaya Therapeutics, and UpToDate; he and Mayo Clinic are involved in an equity/royalty relationship with AliveCor, Anumana, Prolaio, Solid Biosciences, and Thryv Therapeutics. Dr Giudicessi is a consultant for Avidity Biosciences, Citizen Health and Nuevocor Therapeutics; and he is the principal investigator for clinical trials sponsored by Tenaya Therapeutics and Solid Biosciences. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

References

    1. Corrado D., Anastasakis A., Basso C., et al. Proposed diagnostic criteria for arrhythmogenic cardiomyopathy: European task force consensus report. Int J Cardiol. 2024;395 - PubMed
    1. Landstrom A.P., Adekola B.A., Bos J.M., Ommen S.R., Ackerman M.J. PLN-encoded phospholamban mutation in a large cohort of hypertrophic cardiomyopathy cases: summary of the literature and implications for genetic testing. Am Heart J. 2011;161(1):165–171. - PMC - PubMed
    1. Landstrom A.P., Weisleder N., Batalden K.B., et al. Mutations in JPH2-encoded junctophilin-2 associated with hypertrophic cardiomyopathy in humans. J Mol Cell Cardiol. 2007;42(6):1026–1035. - PMC - PubMed
    1. van Opbergen C.J.M., Noorman M., Pfenniger A., et al. Plakophilin-2 haploinsufficiency causes calcium handling deficits and modulates the cardiac response towards stress. Int J Mol Sci. 2019;20(17):4076. - PMC - PubMed
    1. Zheng S.L., Jurgens S.J., McGurk K.A., et al. Evaluation of polygenic scores for hypertrophic cardiomyopathy in the general population and across clinical settings. Nat Genet. 2025;57(3):563–571. - PMC - PubMed

LinkOut - more resources